Hoffman telling Proactive more about Val-083 which has been given fast track designation is also part of the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial which is supporting its development and commercialization. Hoffman also touched on REM-001, which is looking at Recurrent Basal Cell Carcinoma Nevus Syndrome, and what the plan is for 2023.
Kintara Therapeutics looks to advance VAL-083 in the Global Coalition's Phase 2/3 clinical trial
